| DIRECT COMPETITOR COMPARISON | |
| MYGN | ABT | HOLX | Pvt1 | Industry | | Market Cap: | 2.06B | 82.52B | 4.14B | N/A | 50.04M | | Employees: | 869 | 72,000 | 3,959 | N/A | 70 | | Qtrly Rev Growth (yoy): | 10.50% | 10.60% | -3.90% | N/A | 21.40% | | Revenue (ttm): | 350.50M | 30.77B | 1.62B | N/A | 12.73M | | Gross Margin (ttm): | 81.68% | 57.07% | 62.33% | N/A | 50.41% | | EBITDA (ttm): | 142.35M | 8.46B | 583.75M | N/A | -1.76M | | Oper Margins (ttm): | 38.23% | 20.82% | 18.98% | N/A | -7.52% | | Net Income (ttm): | 140.77M | 5.75B | -2.19B | N/A | N/A | | EPS (ttm): | 1.151 | 3.695 | -8.515 | N/A | N/A | | P/E (ttm): | 18.64 | 14.44 | N/A | N/A | 24.44 | | PEG (5 yr expected): | 0.45 | 1.03 | 1.25 | N/A | 1.25 | | P/S (ttm): | 6.04 | 2.68 | 2.53 | N/A | 3.45 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.21 | 0.00% | 56.92B | 12.69 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 54.09 | 0.00% | 15.64B | 18.10 | | Genzyme Corp. | GENZ | 54.87 | 0.00% | 14.56B | 31.28 | | Merck Serono S.A. | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.30 | 0.00% | 41.66B | 16.41 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 47.82 | 0.00% | 8.54B | 59.92 | | Teva Pharmaceutical Industries Limited | TEVA | 57.10 | 0.00% | 50.31B | 52.24 | | Sandoz International GmbH | Private - View Profile |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Watson Pharmaceuticals Inc. | WPI | 38.10 | 0.00% | 4.04B | 19.64 | | King Pharmaceuticals Inc. | KG | 11.44 | 0.00% | 2.84B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.68 | 0.00% | 5.40B | 108.47 | | Pfizer Inc. | PFE | 17.88 | 0.00% | 144.28B | 14.85 | | Johnson & Johnson | JNJ | 62.76 | 0.00% | 173.16B | 14.27 | | GlaxoSmithKline plc | GSK | 38.47 | 0.00% | 97.52B | 12.91 | | Sanofi-Aventis | SNY | 36.29 | 0.00% | 94.76B | N/A | | Novartis AG | NVS | 53.58 | 0.00% | 121.69B | 16.04 | | RHHBY.PK | 41.50 | 0.00% | N/A | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | AstraZeneca plc | AZN | 44.11 | 0.00% | 64.00B | 8.50 | | Abbott Laboratories | ABT | 53.35 | 0.00% | 82.52B | 14.44 | | Bristol-Myers Squibb Company | BMY | 24.25 | 0.00% | 48.04B | 4.51 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | ABT | | Becton Recalls Catheters
Tue 3:49pm -
Zacks.com | | • | ABT | | Health Care: Rx for MBA Job Blues
Tue 8:08am -
BusinessWeek | | • | HOLX | | Hologic to Present at the Raymond James 31st Annual Institutional Investors Conference
Mon, Feb 8 -
PR Newswire | | • | ABT | | CORRECTED - EU expected to clear Abbott, Solvay deal - sources
Mon, Feb 8 -
at Reuters | | • | ABT | | Traders Send Select Stem Cell Shares Soaring
Mon, Feb 8 -
Indie Research | | • | ABT | | Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval
Mon, Feb 8 -
PR Newswire | | • | ABT | | [video] CNBC.com Market Outlook
Fri, Feb 5 -
at CNBC | | • | HOLX | | This Just In: Upgrades and Downgrades
Thu, Feb 4 -
at Motley Fool | | • | HOLX | | 4-Star Stocks Poised to Pop: Myriad Genetics
Thu, Feb 4 -
at Motley Fool | | • | HOLX | | HOLOGIC INC Files SEC form 10-Q, Quarterly Report
Thu, Feb 4 -
EDGAR Online | | • | HOLX | | Stock Picks: Exxon Mobil, Lexmark
Wed, Feb 3 -
at BusinessWeek | | | All Headlines for these symbols... |
|
|
|
1.52% Nasdaq 0.00%
Competitors
